H.C. Wainwright analyst Sean Lee raised the firm’s price target on Novavax (NVAX) to $11 from $10 and keeps a Buy rating on the shares after the company reached an agreement for the transfer of a facility in Maryland to AstraZeneca. Novavax is expected to receive $60M in cash over the next couple of quarters, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax: Sell Rating Due to Declining Vaccine Demand and Financial Challenges
- Novavax Enters Lease Agreement with AstraZeneca
- Novavax announces Maryland-based locations sales for $60M
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge
- Shah Capital pushes for Novavax’s sale on underperformance, Reuters says